[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"wounds-and-injuries--mortality\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:wounds-and-injuries--mortality":37},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":16,"targetDuration":4,"studyType":19,"phases":20,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":26,"lastUpdatePostDateStruct":27,"startDateStruct":30,"completionDateStruct":32,"leadSponsor":34,"locationsCount":5},"100636172",false,"NCT07562230","Rapid Construction of Tissue-engineered Skin for Repairing Difficult-to-heal Wounds","Rapid Construction of Tissue-engineered Skin for Repairing Difficult-to-heal Wounds: A Multicenter Real-world Study","Inclusion Criteria:\n\n* All-age population\n\nWounds requiring surgical repair （single area 10-100 cm²）： acute wounds （burns, traumatic defects, post-scar resection） OR chronic wounds （diabetic foot ulcers, pressure injuries, vascular ulcers）\n\nCompleted wound bed preparation （no necrotic tissue, infection controlled）\n\nSigned informed consent and agreement to use tissue-engineered materials and long-term follow-up\n\nExclusion Criteria:\n\n* History of allergy to allogeneic\u002Fxenogeneic tissue-engineered scaffolds or collagen materials\n\nSevere immunosuppression （HIV\u002FAIDS, long-term immunosuppressant use）\n\nMalignant tumors, uncontrolled systemic infection （CRP \\> 50 mg\u002FL）， or organ failure （Child-Pugh Class C）\n\nMental illness preventing compliance with treatment or follow-up\n\nPregnant or lactating women","ALL",{"count":17,"type":18},1000,"ESTIMATED","INTERVENTIONAL",[21],"NA","This multicenter real-world study evaluates the efficacy and safety of a novel technique for rapid intraoperative construction of tissue-engineered skin using autologous epidermal stem cells （EpiSCs） for repairing difficult-to-heal wounds. Eligible patients are randomized to receive either: （1） the experimental intervention （rapidly constructed EpiSCs-loaded scaffold combined with split-thickness skin graft via one-step or two-step procedure）， or （2） control intervention （acellular scaffold combined with split-thickness skin graft）. The primary outcome is the complete wound healing rate at 4 weeks post-surgery. Secondary outcomes include wound recurrence, scar quality （VSS\u002FPOSAS）， functional recovery （sweat test）， mortality, amputation rate, and safety profile.",[24],"Wounds and Injuries \u002F Mortality","RECRUITING","2026-04-27",{"date":28,"type":29},"2026-05-01","ACTUAL",{"date":31,"type":29},"2026-01-01",{"date":33,"type":18},"2030-12-01",{"name":35,"class":36},"First Affiliated Hospital, Sun Yat-Sen University","OTHER",""]